AMWL

American Well Corp

Add to Watchlist

Advanced Chart

7.360

-0.5(-6.361%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

8.1229

Open

7.900

VWAP

7.51

Vol

62.52K

Mkt Cap

118.88M

Low

7.2501

Amount

469.28K

EV/EBITDA(TTM)

Total Shares

296.46M

-80.13M

EV/OCF(TTM)

P/S(TTM)

0.45

American Well Corporation operates a hybrid care, delivery enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver access to more affordable quality care. It offers a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. The Amwell Converge platform offers data architecture and video capabilities, flexibility and scalability, as well as a user experience focused on the needs of patients, members and providers. For health systems, its enterprise platform enables provider-to-provider virtual care for use cases ranging from stroke to virtual nursing and e-sitting. Its Amwell Carepoint devices enable healthcare providers to leverage proprietary carts and transform existing tablets and TVs into digital access points in clinical settings, helping to address personnel shortages and access limitations.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

64.90M

-2.89%

58.29M

-17.91%

57.47M

-5.86%

Estimates Revision

The market is revising Upward the revenue expectations for American Well Corporation (AMWL) for FY2025, with the revenue forecasts being adjusted by 0.47% over the past three months. During the same period, the stock price has changed by 8.55%.

Revenue Estimates for FY2025

Revise Upward

+0.47%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+8.55%

In Past 3 Month

7 Analyst Rating

34.78% Upside

Wall Street analysts forecast AMWL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMWL is 9.92 USD with a low forecast of 7.50 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

6 Hold

0 Sell

Hold

34.78% Upside

Current: 7.360

Low

7.50

Averages

9.92

High

15.00

34.78% Upside

Current: 7.360

Low

7.50

Averages

9.92

High

15.00

TD Cowen

Hold

downgrade

$12 -> $10

2025-08-06

New

Reason

TD Cowen

Price Target

$12 -> $10

2025-08-06

New

downgrade

Hold

Reason

TD Cowen lowered the firm's price target on Amwell to $10 from $12 and keeps a Hold rating on the shares. The firm updated its model following Q2 results but said while the DHA extension is a positive, its reduced scope which excludes Behavioral health and automated care, is an unfortunate development.

Piper Sandler

Neutral

downgrade

$10 -> $8

2025-05-23

Reason

Piper Sandler

Price Target

$10 -> $8

2025-05-23

downgrade

Neutral

Reason

Piper Sandler lowered the firm's price target on Amwell to $8 from $10 and keeps a Neutral rating on the shares following a positive Q1 print where the company beat revenue and adjusted EBITDA guidance and reaffirmed the 2025 outlook. As of early April, scheduled visits are live across the entire DHA; a considerable achievement delivered on time and on budget, the firm notes. DHA patient and provider satisfaction levels are running in excess of 90.0%. However, due to a leadership transition at the DHA, enterprise-wide deployments of automated programs and digital behavioral health planned for Q2 are expected to be delayed until Q3, Piper says.

UBS

Kevin Caliendo

Neutral

downgrade

$12 -> $9

2025-05-08

Reason

UBS

Kevin Caliendo

Price Target

$12 -> $9

2025-05-08

downgrade

Neutral

Reason

UBS analyst Kevin Caliendo lowered the firm's price target on Amwell to $9 from $12 and keeps a Neutral rating on the shares.

Truist Securities

Jailendra Singh

Hold

Maintains

$12 → $7.5

2025-04-10

Reason

Truist Securities

Jailendra Singh

Price Target

$12 → $7.5

2025-04-10

Maintains

Hold

Reason

Truist lowered the firm's price target on Amwell to $7.50 from $12 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in the Healthcare IT industry. The industry is typically shielded from macro uncertainty, but tariffs and concerns around an economic slowdown have created broader market uncertainty, which is never good for a high-beta highly volatile group like HCIT/Digital Health/Payviders, the analyst tells investors in a research note. Truist adds that while HCIT companies may not be directly exposed to new tariffs, several of these companies serve end markets - hospitals, pharma, etc. - which are likely to see either some direct impact on their supply chain costs or could decide to slow down on their investments.

Truist Securities

Jailendra Singh

Hold

Maintains

$10 → $12

2025-02-14

Reason

Truist Securities

Jailendra Singh

Price Target

$10 → $12

2025-02-14

Maintains

Hold

Reason

Truist raised the firm's price target on Amwell to $12 from $10 and keeps a Hold rating on the shares. The firm is citing improved profitability expectations relative to its prior model while also noting that shares trade at a discount to it's historical average, which is warranted given the lack of clarity on the company's revenue growth acceleration in the out years and breakeven profitability targets, the analyst tells investors in a research note.

Needham

Ryan MacDonald

Hold

Reiterates

n/a

2025-02-13

Reason

Needham

Ryan MacDonald

Price Target

n/a

2025-02-13

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for American Well Corp (AMWL.N) is -1.27, compared to its 5-year average forward P/E of -15.00. For a more detailed relative valuation and DCF analysis to assess American Well Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-15.00

Current PE

-1.27

Overvalued PE

11.23

Undervalued PE

-41.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.01

Current EV/EBITDA

1.60

Overvalued EV/EBITDA

7.82

Undervalued EV/EBITDA

-21.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

5.71

Current PS

0.55

Overvalued PS

13.63

Undervalued PS

-2.20

Financials

Annual

Quarterly

FY2025Q2

YoY :

+12.91%

70.90M

Total Revenue

FY2025Q2

YoY :

-62.11%

-17.84M

Operating Profit

FY2025Q2

YoY :

-62.23%

-18.81M

Net Income after Tax

FY2025Q2

YoY :

-63.10%

-1.24

EPS - Diluted

FY2025Q2

YoY :

-82.49%

-4.72M

Free Cash Flow

FY2025Q2

YoY :

+86.20%

45.32

Gross Profit Margin - %

FY2025Q2

YoY :

-54.15%

-30.68

FCF Margin - %

FY2025Q2

YoY :

-65.80%

-27.55

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

78.0K

USD

3-6

Months

53.9K

USD

6-9

Months

176.6K

USD

0-12

Months

622.1K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

31.1K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

7.7K

Volume

Months

6-9

48.8K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

78.0K

USD

3-6

Months

53.9K

USD

6-9

Months

176.6K

USD

0-12

Months

622.1K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

AMWL News & Events

Events Timeline

2025-08-05 (ET)

2025-08-05

17:48:36

Amwell cuts FY25 revenue view to $245M-$250M from $250M-$260M

2025-08-05

17:46:39

Amwell sees Q3 revenue $53M-$56M, consensus $63.2M

2025-08-05

17:44:58

Amwell reports Q2 EPS ($1..24), consensus ($1.11)

News

9.5

08-06NASDAQ.COM

American Well Corporation (AMWL) Reports Q2 Loss, Beats Revenue Estimates

6.0

08-05Newsfilter

Amwell set to continue to enable U.S. Defense Health Agency healthcare teams to deliver connected and seamless in-person and virtual care for the Military Health System ("MHS")

2.0

06-23NASDAQ.COM

Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains?